Brammer

Freeline Reports First Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, May 30, 2023
Gaucher's disease, CMC, American depositary receipt, Sale, Parini, Daimler Freeline, Patient, Cell, Medicines and Healthcare products Regulatory Agency, Innovation, Safety, MHRA, Dedicated, Pharmaceutical industry, Gaucher, Brammer

LONDON, May 30, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today reported financial results for the first quarter of 2023 and provided a business update.

Key Points: 
  • LONDON, May 30, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today reported financial results for the first quarter of 2023 and provided a business update.
  • “The granting of the ILAP designation by UK regulators further highlights the significant need for more effective and less burdensome therapies for people with Gaucher disease.
  • “Importantly, we continue to make significant strides as a company in driving greater focus, financial discipline, and operational efficiency,” Parini continued.
  • Cash position: As of March 31, 2023, unrestricted cash and cash equivalents were $55.4 million, compared to $47.3 million as of December 31, 2022.

UMD to Present Climate Finance and Risk Management Bootcamp

Retrieved on: 
Wednesday, June 8, 2022
Risk management, Faculty, Natural science, University of Maryland College of Computer, Mathematical, and Natural Sciences, Robert H. Smith School of Business, Program, College Park, Research, School, Doctor of Philosophy, Brammer, MBA, Business, Climate finance, Climate, Computer, Smith School, University, CMNS, Growth, Weather, College, IPCC, SEC, Industry, Learning, UMD, Climate change, History of the University of Maryland, College Park, Education, Communication, Management, Financial adviser, Zoom, Mathematics

COLLEGE PARK, Md., June 8, 2022 /PRNewswire/ -- As climate change increasingly affects business decision making, risk managers, financial analysts and other leaders must anticipate how weather events may impact their growth outlook, estimate how port taxes may increase because of rising sea levels, develop contingencies for supply chain disruptions and respond to the unexpected.

Key Points: 
  • To give business leaders expertise in climate change and risk management, the University of Maryland will present a Climate Finance and Risk Management Bootcamp , on consecutiveThursdays, June 23 and June 30, 2022.The 10 a.m.-3 p.m. sessions, via Zoom, will be delivered by faculty experts in the University of Maryland's Robert H. Smith School of Business and College of Computer, Mathematical, and Natural Sciences (CMNS).
  • We want to educate these industry practitioners on the fundamentals of what it takes to conduct climate risk disclosures that the SEC will impose on many companies and related climate financial and risk analytics."
  • For more information and to register for the June 23 and June 30 Climate Finance and Risk Management Bootcamp, go to the program homepage .
  • For a preview, watch the recent Climate Finance and Risk Management Webinar featuring Rossi, Canty and Brammer.

Sangamo Announces Agreement Securing Access To Large-Scale, Commercial-Grade Manufacturing Capacity At Brammer Bio

Retrieved on: 
Tuesday, April 2, 2019
Branches of biology, Biology, Genetics, Fabry disease, Gene therapy, Brammer

"The facility we are building in Brisbane and our expanded access to commercial-grade supply through Brammer Bio will allow us to continue to meet our quality, cost and timeline goals."

Key Points: 
  • "The facility we are building in Brisbane and our expanded access to commercial-grade supply through Brammer Bio will allow us to continue to meet our quality, cost and timeline goals."
  • The agreement with Brammer Bio provides Sangamo with access to dedicated AAV manufacturing capacity up to 2000-L bioreactor scale capable of handling large-scale, commercial -grade runs for products such as ST-920, Sangamo's gene therapy product candidate for Fabry disease.
  • The agreement also allows Sangamo to leverage Brammer Bio's viral vector manufacturing know-how in the new Sangamo facility in Brisbane in order to provide a seamless transition from early development to late-stage clinical trials and commercial-scale manufacturing.
  • "Brammer Bio and Sangamo have worked together for more than a decade, and we are pleased to continue to expand our strong relationship through this agreement," said Mark Bamforth, president and CEO of Brammer Bio.